Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4874794 | 0.77 | TP53 (0.50) | TP53ENPP2CYP3A4CYP2C9KMT2A | |
| SCHEMBL4881669 | 0.70 | MAPT (0.51) | TP53ENPP2KMT2AMAPTLMNA | |
| SCHEMBL4881920 | 0.69 | TP53 (0.47) | TP53ENPP2KMT2AMAPTLMNA | |
| SCHEMBL4882847 | 0.66 | ENPP2 (0.66) | TP53ENPP2KMT2AMAPT | |
| SCHEMBL14024418 | 0.66 | TSHR (0.54) | TP53CYP3A4CYP2C9KMT2AMAPT | |
| SCHEMBL13235183 | 0.65 | MAPT (0.58) | TP53ENPP2KMT2AMAPTLMNA | |
| SCHEMBL4884595 | 0.65 | LMNA (0.71) | TP53ENPP2KMT2AMAPTLMNA | |
| SCHEMBL4883373 | 0.65 | MAPT (0.59) | TP53ENPP2KMT2AMAPT | |
| SCHEMBL4884603 | 0.65 | LMNA (0.71) | TP53ENPP2KMT2AMAPTLMNA | |
| SCHEMBL4875036 | 0.63 | TP53 (0.59) | TP53ENPP2KMT2AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1698335-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DISEASE IN WHICH MITOCHONDRIAL BENZODIAZEPINE RECEPTOR PARTICIPATES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | MTNR1A, GSR, NLN | TP53 2534/4885ENPP2 2226/4885CYP3A4 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.